Avonex

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Currently, products containing interferon beta (IFNβ) are injected either intramuscularly or subcutaneously. To avoid the… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2011
2011
Interferon-β (IFN-β) is a current effective treatment for multiple sclerosis (MS) and exerts its therapeutic effects by down… (More)
Is this relevant?
2010
2010
We aimed to compare the therapeutic effect of Avonex (Av), Betaferon (Be) & Rebif (Re) on the Expanded Disability Status Scale… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2007
2007
To determine the safety of a combination of mycophenolate mofetil (Cellcept, MMF) and IFNbeta-1a (Avonex) in relapsing-remitting… (More)
Is this relevant?
2006
2006
OBJECTIVES To compare the relative efficacies of Betaferon, Avonex, and Rebif in the treatment of relapsing-remitting multiple… (More)
Is this relevant?
2005
2005
An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNbeta-1a-Avonex) was conducted to… (More)
Is this relevant?
2004
2004
BACKGROUND A new liquid formulation of Avonex (interferon beta-1a [IFNbeta-1a]) in a prefilled syringe has been developed to make… (More)
Is this relevant?
Review
2002
Review
2002
The past decade has seen unprecedented advances in the development of disease-modifying therapies for relapsing-remitting… (More)
Is this relevant?
2001
2001
The Controlled High Risk Avonex Multiple Sclerosis Study (CHAMPS) tested whether interferon beta la (Avonex) treatment would… (More)
Is this relevant?
1998
1998
The aim of this 1 week study was to compare the biologic effects induced by Betaseron and AVONEX using their approved dose, route… (More)
Is this relevant?